Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1036 to 1050 of 1364 results for social care

  1. Ribociclib in combination with endocrine therapy and goserelin for previously untreated hormone receptor-positive, HER2-negative advanced breast cancer in premenopausal women (ID1307)

    In development Reference number: GID-TA10261 Expected publication date: TBC

  2. Tralokinumab for treating moderate to severe atopic dermatitis [ID3734]

    Discontinued Reference number: GID-TA10596

  3. Public board meeting agenda and papers: December 2025

    Agenda and papers of the NICE public board meeting on 10 December 2025

  4. Public board meeting agenda and papers: March 2023

    Agenda and papers of the NICE public board meeting on 22 March 2023

  5. Public board meeting agenda and papers: March 2024

    Agenda and papers of the NICE public board meeting on 20 March 2024

  6. Public board meeting agenda and papers: December 2023

    Agenda and papers of the NICE public board meeting on 13 December 2023

  7. Public board meeting agenda and papers: July 2023

    Agenda and papers of the NICE public board meeting on 19 July 2023

  8. Aixplorer ShearWave Elastography for ultrasound imaging and assessing suspicious breast lesions (MIB15)

    NICE has developed a Medtech Innovation Briefing (MIB) on Aixplorer ShearWave Elastography for ultrasound imaging and assessing suspicious breast lesions

  9. Benralizumab for previously treated severe nasal polyps [ID1659]

    In development Reference number: GID-TA10818 Expected publication date: TBC

  10. Durvalumab with tremelimumab for untreated PD-L1-positive urothelial bladder cancer [ID1335]

    Discontinued Reference number: GID-TA10315

  11. Elivaldogene autotemcel for treating cerebral adrenoleukodystrophy [ID1284]

    Discontinued Reference number: GID-HST10038

  12. CFHealthHub for managing cystic fibrosis during the COVID-19 pandemic (MIB219)

    NICE has developed a medtech innovation briefing (MIB) on CFHealthHub for managing cystic fibrosis during the COVID-19 pandemic .

  13. Nintedanib for untreated malignant pleural mesothelioma [ID1424]

    Discontinued Reference number: GID-TA10359

  14. Mogamulizumab for previously treated T-cell leukaemia-lymphoma [ID1390]

    Discontinued Reference number: GID-TA10464

  15. Tanezumab for treating moderate to severe chronic pain caused by osteoarthritis [ID1603]

    Discontinued Reference number: GID-TA10711